NCT01381822View on ClinicalTrials.gov

Dose-Escalation Study of TH-302 in Combination With Sunitinib to Treat Patients With Advanced Renal Cell Carcinoma,Gastrointestinal Stromal Tumors and Pancreatic Neuroendocrine Tumors

PHASE1UnknownINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Advanced Renal Cell CarcinomaGastrointestinal Stromal TumorsPancreatic Neuroendocrine Tumors
Interventions
DRUG

TH-302

TH-302: administered by IV infusion over 30 or 60 minutes on Days 8, 15 and 22 of a 42 day cycle.

Trial Locations (2)

46526

IU Health Goshen Center for Cancer Care, Goshen

52242

University of Iowa, Iowa City

Sponsors
All Listed Sponsors
lead

Threshold Pharmaceuticals

INDUSTRY